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African trypanosomosis is a chronic debilitating disease affecting the health and economic well-being of developing countries.
The immune response during African trypanosome infection consisting of a strong proinflammatory M1-type activation of the
myeloid phagocyte system (MYPS) results in iron deprivation for these extracellular parasites. Yet, the persistence ofM1-typeMYPS
activation causes the development of anemia (anemia of chronic disease, ACD) as a most prominent pathological parameter in
the mammalian host, due to enhanced erythrophagocytosis and retention of iron within the MYPS thereby depriving iron for
erythropoiesis. In this review we give an overview of how parasites acquire iron from the host and how iron modulation of the host
MYPS affects trypanosomosis-associated anemia development. Finally, we also discuss different strategies at the level of both the
host and the parasite that can/might be used to modulate iron availability during African trypanosome infections.
1. Introduction
Iron is a vital nutrient required by nearly every living
organism ranging from archaea to eukaryotes. It is an
essential cofactor present in heme groups and iron-sulphur
clusters and impacts on a broad range of important biologi-
cal/metabolic processes including host and pathogen cellular
functions, erythropoiesis, and immunity.The capacity of iron
to fluctuate between two oxidation states, ferrous (Fe2+) and
ferric (Fe3+), makes it indispensable for many critical biolog-
ical processes, including nucleic acid synthesis/DNA replica-
tion, lipid synthesis, protein translation, energy metabolism
(cytochrome respiration), oxygen sensing/transport, and oxi-
dant defense [1, 2]. Yet, the distinct oxidative state properties
of iron which make iron indispensable also can contribute to
toxicity to cells, because of its ability to promote the formation
of damaging oxidative radicals. Indeed, the redox cycling
of ferrous and ferric iron in the physiological presence of
H
2
O
2
in the cells results in the formation of reactive oxygen
intermediates/free radicals (such as hydroxyl radicals) via
the Fenton reaction which in turn can damage lipids, DNA,
proteins, and other cellular components. Therefore, regula-
tory interactions between host iron homeostasis (quantity
and subcellular location) and immune function are crucial,
since both iron deficiency and iron excess can compromise
cellular functions [3]. Access to iron is particularly important
in the context of host-pathogen interactions. Indeed, when
confronted with infection and inflammation the mammalian
host reallocates its iron reservoirs in an effort to deprive
invading intracellular or extracellular pathogens of iron [4, 5].
Thus, the control over iron homeostasis is a central battlefield
in the course of an infectious disease [6, 7]. The host
immune system can regulate iron availability for pathogens
via activation of cytokines, cellular proteins/peptides, and
hormones, hereby gaining control over pathogen prolifera-
tion and strengthening specific immune effector pathways, a
strategy also termed “nutritional immunity” [6, 8, 9].
In this review we will give an overview of the role of iron
homeostasis/modulation during African trypanosomosis,
which is a chronic debilitating disease affecting the health
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and economic well-being of many people in developing
countries [10–12]. It is caused by strictly extracellular/free-
living flagellated unicellular parasites, which are etiologic
agents of highly disabling and often fatal diseases of humans
(i.e., Human African trypanosomosis, HAT) and livestock
(i.e., Animal African trypanosomosis, AAT, or nagana).
As recently reviewed [13], African trypanosomes produce
a number of components that modulate the mammalian
host immune response. In particular, they manipulate cells
of the myeloid phagocytes system (MYPS) which includes
myeloid cells of the mononuclear phagocytes system (MPS,
i.e., macrophages, monocytes, and immature DCs) as well
as granulocytes (neutrophils) [14] and thereby affect the
capacity of the host to (i) control parasite growth (referred to
as resistance to infection) and (ii) to limit tissue pathogenicity
caused by the immune response mounted for resistance to
infection (referred to as (trypano)tolerance to infection).
Trypanotolerance is associated with the sequential induction
of IFN-𝛾 and MyD88-dependent M1-type myeloid cells (i.e.,
classically activatedmyeloid cells) producingTNF and/orNO
which reduce the fitness of the parasite and ensure parasite
control, followed by a switch to IL-10 dependent M2-type
myeloid cells (i.e., alternatively activatedmyeloid cells) ensur-
ing pathogenicity control [15]. In contrast, trypanosuscepti-
bility is associated with a persistence ofM1-type myeloid cells
and an inability to switch to M2-type myeloid cells, which
culminates in pathogenicity. In natural and experimental
hosts, the control of the African trypanosome load, and thus
resistance to infection, is less of a problem than the control
of the immune response to mount tolerance to the disease.
In this review, we will focus on how African trypanosomes
acquire ironwithin themammalian host and how ironmodu-
lation in hostmyeloid cells affects trypanosomosis-associated
pathogenicity development, whereby anemia development is
one of the most prominent parameters.
2. Iron Homeostasis/Acquisition in
the African Trypanosome
Trypanosomatids comprise a large group of flagellated uni-
cellular protozoa with a free-living and parasitic lifecycle.
The 3 major human diseases caused by trypanosomatids are
African trypanosomosis (sleeping sickness caused by Try-
panosoma brucei sp.), SouthAmerican trypanosomosis (Cha-
gas’ disease caused byTrypanosoma cruzi), andLeishmaniasis
(caused by different species of Leishmania). With respect to
the parasites that are the main focus of this review, members
of the T. brucei complex are transmitted by tsetse flies of
the genus Glossina spp., which are only present in equatorial
Africa. These members can be further divided into the (i)
human pathogens T. b. gambiense and T. b. rhodesiense and
(ii) animal pathogens causing either nagana, which is mainly
caused by T. b. brucei, T. congolense, and T. vivax, or surra (T.
evansi) or dourin (T. equiperdum). Of note, the trypanosomes
of equines (T. equinum and T. equiperdum) and of camels
(T. evansi) are not transmitted by tsetse flies but by direct
contact during copulation of horses by biting insects such as
horse flies (tabanids). The two HAT causing parasites, T. b.
rhodesiense and T. b. gambiense, do not only differ at the level
of their geographical distribution; they also differ biologically,
clinically, therapeutically, and epidemiologically and cause
separate diseases. Indeed, T. b. gambiense infection (account-
ing for over 95% of cases) is found in West and Central
Africa and progresses at a more indolent pace (up to 3 years)
than that of T. b. rhodesiense (accounting for the remainder
of cases) causing an acute, rapidly progressive infection
(within 6 months) in eastern and southern Africa [11, 21].
Both infections are characterized by two stages, whereby in
the first stage parasites are observed in the hemolymphatic
system, producing fever, splenomegaly, adenopathies, and
cardiac, neurological, and psychological disorders. In the
second stage, trypanosomes are distributed in the central
nervous system (CNS) leading to several sensory, motor, and
psychic disorders and ending in death if untreated [11, 22]. For
gambienseHAT, human beings are themain reservoir and the
predominant mode of transmission is by tsetse flies although
sexual and congenital transmission was also reported [23].
Rhodesiense HAT, however, is a zoonosis, a “disease or
infection naturally transmitted between vertebrate animals
and humans,” whereby the transmission cycle thus involves
mainly transmission between nonhuman reservoirs by tsetse
flies, with occasional animal-tsetse-human transfer. Since
T. b. rhodesiense and T. b. gambiense are morphologically
identical and also resemble T. b. brucei (a subspecies causing
nagana), the majority of research used T. b. brucei as a model.
However, this might not always reflect what is happening
in the case of HAT. Identification of both HAT species is
based on specific molecular diagnosis markers, that is, the
serum resistance-associated (SRA) gene which is restricted
to T. b. rhodesiense parasites and the T. b. gambiense specific
gene (TGSGP) which is restricted to T. b. gambiense [24, 25].
Alternatively, T. b. gambiense can also be diagnosed based on
antibodies. According toWHO (World Health Organization,
specialized agency of the United Nations serving as the
directing and coordinating authority for international health
matters and public health), HAT brings about 6 million
people at risk of infection within the 36 affected African
countries, most of them in rural areas of extreme poverty
[22, 26]. Around 300,000 people are currently infected with
trypanosomes and 10,000–40,000 of them die every year
[11, 27]. Regarding AAT, the economic losses are estimated
to be about US$ 1.2 billion per year due to major problems
in agricultural and nutritional development of endemic
areas [28]. Furthermore, the lack of prospect for vaccine
development against African trypanosomosis is strengthened
by (i) the fact that pharmaceutical companies are less prone
to engage/invest in drug discovery/development of diseases
that affect the poorest people, (ii) the political instability of
the affected regions, (iii) the fact that wild animals function
as reservoir of the parasite and therefore hamper the control
of the disease, and (iv) the inappropriate use of the available
drugs resulting in the emergence of drug resistance [29–
31]. Nevertheless, so far chemotherapy remains the only
therapeutic choice for these diseases, whereby they target
unique organelles of trypanosomes such as glycosomes and
the kinetoplast that are absent in the mammalian host or
trypanosome metabolic pathways that differ from the host
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Figure 1: Lifecycle of African trypanosomes. Tsetse flies become infected following a blood meal taken from a trypanosome infected
mammalian host. The parasites that are taken up reach the midgut together with the blood meal. Subsequently, only the short stumpy
(non-dividing) forms of the parasite that are preadapted to the changed environment within the tsetse fly will be able to differentiate
into procyclic forms. The multiplying procyclic forms colonize the ectoperitrophic space, after which they migrate to the salivary glands
via the proventriculus lumen to move into the foregut and proboscis. During this migration, the procyclic forms in the fly differentiate
into epimastigote forms that within the salivary glands attach to the epithelium and proliferate, giving rise to metacyclic forms which
are preadapted for survival into the mammalian host [16, 17]. Upon a blood meal on a new host, the parasites will be inoculated and
differentiate into a long slender (dividing) form. Within the mammalian host long slender forms multiply via binary fission, giving rise
to a first peak of parasitemia. When the trypanosome population reaches a sufficiently high density, a quorum sensing-like mechanism elicits
the differentiation of long slender forms into short stumpy forms that allow transmission following uptake by a new tsetse fly [18, 19]. During
the entire lifecycle of trypanosomes, there is a continuous fight for iron acquisition at the level of both the parasites and the host. Image
generated by Joar Pinto.
Table 1: Overview of the metabolic changes and differences in energy/iron source used by African trypanosomes during their lifecycle.
Long slender form Short stumpy form Procyclic form
Stage Proliferative Quiescent Proliferative
Surface coat VSG VSG Procyclin (PE/GPEET)
Mitochondrium Repressed Repressed/enlarged Active
Citric acid/respiratory chain
enzymes Absent Present but not fully active Present and activated
Energy source D-Glucose D-Glucose L-Proline
Iron source Tf, Lf, heme, andheme-containing proteins
Tf, Lf, heme, and
heme-containing proteins
heme, heme-containing
proteins
counterparts (carbohydrate metabolism, protein and lipid
modifications, and programmed cell death) [32].
African trypanosomes have a strictly extracellular het-
eroxenous life cycle alternating between the intestine of the
tsetse fly and the blood/tissues of the mammalian host (see
Figure 1), whereby they exist as procyclic or trypomastigote
forms, respectively [33]. Briefly, upon a bite of a trypanosome
infected tsetse fly, metacyclic parasites are inoculated into
the blood circulation of the mammalian host. The parasites
immediately differentiate into long slender forms (dividing
forms), which are adapted to survival in the glucose-rich and
highly oxygenated blood of the host and multiply, thereby
giving rise to a first parasitemia peak. Once a peak is
reached, most likely due to quorum sensing [34], the long
slender parasites differentiate into short stumpy forms (non-
dividing forms), which are preadapted for survival in the
tsetse fly vector (see Figure 1). Within the tsetse fly vector
the parasites differentiate into procyclic forms which are
adapted to survive in the proline-rich (carbon source) and
low oxygenated environment. To this end, trypanosomes
undergo important metabolic and morphological changes
to adapt to the growth conditions imposed by the different
hosts and environments they inhabit (Table 1) [33]. They
have acquired elaborate mechanisms to adapt/survive in the
different hosts such as fine tuning of energy metabolism,
organelle reorganization, dedicated nutrient uptake, and
biochemical and ultrastructural remodeling [35–38]. In par-
ticular, pathogenic trypanosomes have developed different
mechanisms to guarantee iron supply from their host [39–41].
2.1. Iron Homeostasis/Acquisition by Bloodstream T. brucei
Parasites. Trypanosomes in contrast to mammalian cells
only require small amounts of iron [40], due to the fact
that the bloodstream form lacks cytochromes and contains
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only 4 iron-dependent enzymes (aconitase, alternative oxi-
dase, ribonucleotide reductase, and superoxide dismutase)
[42–46]. Within the bloodstream of the mammalian host,
trypanosomes scavenge iron via a high affinity receptor-
mediated endocytosis of iron-bound transferrin (Tf), which
is referred to as holo-Tf [47, 48].This heterodimeric transfer-
rin receptor (Tf-R), which is unable to discriminate between
holo- and apo-Tf (iron-free Tf) [39, 49, 50], is encoded by
the expression-site-associated genes (ESAG) 6 and 7, whereby
the Tf-R protein is composed of one molecule of pESAG6
containing a COOH-terminal glycosylphosphatidylinositol
(GPI) membrane anchor and one molecule of pESAG7
devoid of this modification [51, 52]. The heterodimer binds
one molecule of Tf giving rise to a ternary complex. This low
abundant glycoprotein (about 3000molecules/cell) is located
in the flagellar pocket and its expression is regulated by iron
availability and posttranscriptional control mechanisms that
does not involve the IRE/IRP1 (iron regulatory proteins/iron
responsive elements) system typical for mammals [52, 53].
It was shown that iron starvation (using iron chelators
or species specific Tf) leads to a 3–10-fold upregulation
of Tf-R with a concomitant redistribution of the receptor
from the flagellar pocket to the entire parasites’ surface
[52, 54]. Furthermore, it was shown that during chronic
trypanosomosis in cattle the host Tf level is decreased, yet
the bloodstream pathogens develop the ability to grow at very
low iron concentrations by increasing their Tf-R expression
levels thereby allowing higher Tf uptake [54, 55]. In addition,
T. b. brucei has about 15 VSG expression sites (VSG-ES);
only one is transcribed at a given time, while the others
remain repressed, providing the expression of a particular
combination of ESAGs in a mutually exclusive manner. The
transcriptional activation/inactivation of genes in the VSG-
ESs is a highly regulated mechanism, potentially allowing
the parasite to quickly respond to any environment change.
Furthermore, the different copies of ESAG6/7 sequences are
highly polymorphic in regions corresponding to Tf binding
sites, whereby small changes in the amino acids present in
the surface exposed-loops drastically affect the affinity of the
receptor for a given Tf, thereby contributing to an additional
mechanism of trypanosomes to acquire iron and to permit
their rapid adaptation in distinct hosts [56, 57]. Importantly,
similar observations as for the T. b. brucei parasites with
respect to the ESAG6/7were observed for theT. b. rhodesiense
and T. b. gambiense parasites [58, 59]. This Tf-R polymor-
phism which allows selecting for high affinity Tf-Rs together
with the rapid recycling of Tf-R and gene-specific activation
events enables trypanosomes to efficiently compete for limit-
ing substrate and withstand iron deprivation until a new set
of Tf-R is expressed [55, 60, 61].TheTf-Rwhich has an affinity
50–1000 nM formouse/human Tf is exclusively present in the
mammalian bloodstream stage form of the parasite and its
structural organization differs completely from the mammal
counterpart [58, 62]. Following binding of iron-bound Tf, the
Tf-R is endocytosed in a temperature- and energy-dependent
manner, which involves proteins like dynamin, epsin, the
adaptor AP-2, the small GTPase TbRab5A, 𝛽-adaptin, and
clathrin [63–65]. In addition, it was suggested that the
phosphatidylinositol-3 kinase (PI-3K) TbVPS34 also plays
a role in Tf trafficking, possibly downstream of TbRAb5A
GTPase [66]. Upon cleavage of the intracellular GPIs by the
GPI-phospholipase C (GPI-PLC) expressed in bloodstream
T. brucei, producing diacylglycerol (DAG) and inositolphos-
phoglycan, DAG receptors are activated. Subsequently, the
DAG signaling pathway is activated that depends on protein
tyrosine kinase (PTK) for the activation of proteins in the
endocytic system by the phosphorylation of clathrin, actin,
adaptins, and other components of thismachinery [67]. It was
suggested that DAG stimulation of Tf uptake may contribute
to parasite virulence by aiding T. brucei to acquire sufficient
amounts of Tf (i.e., iron) to sustain its extracellular existence
and compete with host cells for Tf in the blood [67]. Due
to acidification within the endosomes, the iron is released
from Tf, while the ESAG6/7 Tf-R complex loses affinity for
apotransferrin [68]. Subsequently, while (apo)transferrin is
delivered to the lysosome and proteolytically cleaved via a
T. brucei cathepsin B-like protease TbcatB [53, 69, 70] and
degraded fragments are exported/exocytosed from the cell
via TbRAb11 positive recycling vesicles [71], the ESAG6/7
Tf-R is recycled back to the flagellar pocket via TbRAb11
positive recycling vesicles [72]. This is in contrast to the
uptake of mammalian iron-bound Tf where the entire Tf-TfR
complex is recycled to the cell surface (see later). How iron
gets from the endolysosomal system to the cytoplasm is under
investigation, but this involves possibly divalent metal ion
transporters as in the mammalian host (see later). Given that
Tf-bound iron (Fe3+) is practically insoluble at physiological
pH and temperature, it must first be reduced to Fe2+, most
likely through a ferric reductase, in order to be exported from
the endolysosomal system into the cytoplasm. Interestingly,
in the T. brucei genome, two putative ferric reductases have
been found, a cytochrome b561-type (Tb927.6.3320) and an
NADPH-dependent flavoprotein (Tb11.02.1990), which could
act in cooperation with some divalent putative cation trans-
porters [39]. In this context, recently, Taylor et al. [73] showed
that a T. brucei Mucolipin-like protein TbMLP, orthologous
to the mammalian endolysosomal cation channel Mucolipin
1, is involved in import of iron into the cytosol of African
trypanosomes. It is expressed in both bloodstream and insect
stages of the parasite and is confined to the endocytic system,
with the highest expression being found in the p67-positive
compartment (i.e., the lysosome). Yet, they also indicate that
even when TbMLP expression is greatly reduced, there is
sufficient iron import. Thus, an alternative mechanism to
provide the parasite with an adequate supply of cytosolic
iron needed for synthesis of iron-containing proteins is not
excluded. For instance, it is suggested that intracellular iron
is not homogeneously distributed. Excess iron is presumably
transported to a storage compartment from which it can be
released if cytosolic iron falls under a certain level.The signal
for Tf-R upregulation could, therefore, come from a decrease
in cytosolic iron. How the trypanosome monitors cytosolic
iron is not known; however, cytosolic aconitase, the iron
sensor in mammalian cells, is not involved in T. brucei iron
sensing.
Besides the Tf-R, T. brucei parasites can also acquire iron
via the uptake of iron-binding Lactoferrin (LF), a member
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of the Tf family protein found in most biological fluids of
mammals and secondary granules of polymorphonuclear
cells (PMN) [74]. One of the receptors involved in LF binding
was glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
[74], an enzyme typically involved in catalyzing several steps
in glycolysis (i.e., breakdown of glucose for energy and
carbon molecules) and also found to be involved in several
nonmetabolic processes including transcription activation
and initiation of apoptosis. It is considered to be a member of
the moonlighting or multifunctional proteins [75]. Iron can
also be acquired via the uptake of heme, which consists of a
cyclic tetrapyrrole ring (protoporphyrin IX) that coordinates
an iron atom which can adopt Fe3+ or Fe2+ oxidation
states. This essential cofactor for proteins is involved in
oxygen transport and storage (hemoglobin and myoglobin),
mitochondrial electron transport (complexes II–IV), steroid
metabolism (cytochromes), signal transduction (nitric oxide
synthase), and transcription and regulation of antioxidant-
defense enzymes (e.g., superoxide dismutase, catalase, and
peroxiredoxins). Heme is also a regulatorymolecule involved
in gene transcription/translation [76, 77]. Given that try-
panosomes are auxotrophic for heme [78], they have adapted
their heme-dependent metabolic pathways (biosynthesis of
sterols and polyunsaturated fatty acids, respiration, oxida-
tive stress response, and detoxification) to fluctuations in
nutritional availability across their life cycle [77]. Host heme
cannot diffuse through the parasites’ membrane due to the
fact that it contains cationic carboxylate side chains. Thus,
trypanosomes have evolved high affinity heme-binding pro-
teins on their cell surface. To this end, the parasites express an
haptoglobin-hemoglobin receptor (HpHbR), which is linked
to the plasma membrane through a C-terminal GPI anchor
and localized in the flagellar pocket of bloodstream parasites
only [79, 80]. HpHbR also plays a central role in determining
whether humans can be infected by trypanosomes [79]. Most
species of trypanosomes, such as T. b. brucei, are unable
to infect humans due to the trypanolytic serum protein
apolipoprotein-L1 (APOL1) delivered via two trypanosome
lytic factors (TLF-1 and TLF-2). Binding of TLF1 to the
HpHbR results in endocytosis and lysosomal localization
of the toxin, apoL-I, and subsequent death of the parasite.
However, T. brucei rhodesiense and T. brucei gambiense
have managed to resist this lysis mechanism. Indeed, T.
brucei rhodesiense expresses the ApoL1 neutralizing serum
resistance-associated (SRA) protein, which is a truncated
version of the variant surface glycoprotein (VSG), which
binds to APOL1 in the lysosome and hence prevents lysis
[81].T. brucei gambiense has besides a single highly conserved
amino acidmutation in the TbgHpHbR thereby ablating high
affinity TLF-1 binding and subsequent endocytosis, also a T.
b. gambiense specific gene, TgsGP, which is also a truncated
version of VSG [82]. With respect to heme transport and
distribution in trypanosomes, these mechanisms remain so
far elusive. Moreover, since African trypanosomes lack heme
oxygenase and ferrochelatase required for heme catabolism
and extraction of iron, the simplest explanation could be that
scavenged heme is incorporated directly into heme-proteins
which are distributed throughout different subcellular com-
partments without intermediate steps [78].
2.2. Iron Homeostasis/Acquisition by Insect Stage T. brucei
Parasites. Switching from the mammalian host nutrient rich
environment to the tsetse fly vector nutrient-poor environ-
ment requires a change in the energy metabolism of the
parasites in order to survive. In contrast to the bloodstream
form stage of trypanosomes where iron uptake occurs mainly
via a Tf-Rmediatedmechanism, the iron uptakemechanisms
in the procyclic insect stage form of T. brucei are less
characterized. It is accepted that procyclic forms efficiently
take up iron from ferric complexes via a reductivemechanism
[83]. Surprisingly, although the insect stage requires more
iron, the rate of endocytosis is greatly reduced compared to
the bloodstream stage [35, 84]. This can be explained by the
activation of a mitochondrial respiratory chain for energy
metabolism in the insect life stage of the parasite [43, 85];
the bloodstream form of T. brucei shows a rudimentary
mitochondrion but through the activity of an alternative
oxidase and well-developed glycosomes depends on glycol-
ysis for its energetic metabolism while the procyclic form of
T. brucei presents a well-developed mitochondrion and low
glycosomal activity. Given that the procyclic form (i) requires
active mitochondria which are one of the most important
heme-protein containing organelles and (ii) resides in the
midgut of the tsetse flywhere hemoglobin digestion following
a bloodmeal results inmassive release of free heme, uptake of
heme or heme-containing proteins might be more important
in this stage [86, 87]. The T. brucei vacuole protein sorting
41 (TbVPS41) plays an important role in the intracellular
iron utilization system as well as the maintenance of normal
cellular morphology in the procyclic form of the parasite
[88]. In addition, it was shown that iron-sulphur (FeS) cluster
proteins involved in a variety of cellular processes including
electron transport and gene expression, such as the Rieske
protein and cytochrome c reductase (complex III), in which
iron atoms in different activation states are coordinated
with inorganic sulphur in addition to cystein thiol groups,
contribute to incorporation of heme into apo/heme-proteins
[78, 89], which are involved in essential metabolic pathways
like biosynthesis of sterols and polyunsaturated fatty acids
(PUFAs) carried out in the endoplasmic reticulum (ER) and
respiratory complexes in the mitochondrion [77].
3. Iron Homeostasis/Acquisition in
the Mammalian Host during Steady-State
Situation
Given that African trypanosomesmultiply in themammalian
bloodstream as extracellular parasites, they continuously
depend on host nutrient supply but are also confronted with
the host’s immune system. Hereby, the mammalian host
immune system regulates iron availability for pathogens to
gain control over pathogen proliferation and to strengthen
the specific immune effector mechanisms via cytokines,
cellular proteins/peptides, and hormones. Over the years, the
molecular mechanisms involved in the regulation of iron
homeostasis in the mammalian host have become increas-
ingly clear [90, 91].These mechanisms are summarized in the
next paragraph since they provide the conceptual framework
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for our investigations into the role of iron in host-African
trypanosome interactions.
Free iron or heme-bound iron uptake/absorption occurs
primarily in the duodenum across the apical mucosa of
duodenal epithelial cells, whereby intestinal heme ironuptake
occurs through the interaction with the heme carrier protein
(HCP1). The iron in the heme is then released within the
enterocytes via the action of the heme catabolizing enzyme
heme oxygenase (HO-1) and the dietary ferric iron (Fe3+)
is reduced to the ferrous (Fe2+) state by ferric reductases at
the level of the enterocytes [92, 93]. Subsequently, ferrous
iron is transported into the cell via the divalent metal ion
transporter 1 (DMT1, Nramp2 (natural resistance-associated
macrophages protein)/solute carrier family 11, member 2
(SLC11A2)), after which it can be used for cellular processes
or stored intracellularly by ferritin or exported from the cell
at the basolateral membrane to the plasma via the sole iron
exporter ferroportin-1 (FPN-1, SLC40A1), depending on the
hosts’ requirements for iron. Associated with ferroportin is
the enzyme hephaestin (a copper-containing ferroxidasewith
homology to ceruloplasmin (see later)) which oxidizes the
ferrous form back to the ferric form. Once in the circulation,
liver secreted Tf will bind one or two ferric iron molecules
and transport iron in the serum and extravascular spaces
where it serves as a source of iron for cells and tissues
that are perfused by the systemic circulation, including
liver, heart, muscle, kidney, and bone marrow. Hereby, two
main factors determine iron absorption; (i) the amount of
iron present in body stores and (ii) the need of iron for
hematopoiesis/erythropoiesis [94]. Important to mention is
that the amount of iron absorbed via alimentation is insuffi-
cient to meet the daily physiologic needs of the body. There-
fore, the bulk of iron needed for homeostasis (mainly for
red blood cell (RBC) production) is provided by the MYPS,
more specifically the myeloid cells, that recycles senescent
RBCs at the level of the liver, spleen, and bone marrow via
erythrophagocytosis and allows their iron reutilization [95]
(see Figure 2). The majority of the body iron in mammals is
sequestered intracellularly and complexed within the heme
moiety of hemoglobin inside RBCs. Catabolism of RBCs
results in heme release which in turn is further processed
via heme-oxygenase 1 (HO-1) to give rise to equal amounts
of iron, biliverdin, and carbon monoxide [96]. Once iron
is released from heme it follows the same pathway as iron
released from the holo-Tf/Tf-R complex, whereby it is either
stored in the cell by ferritin or exported via ferroportin-1 (see
further). Under physiological conditions, iron recycling by
macrophages accounts for approximately 95% of the daily
needs of iron for erythropoiesis and other physiological
processes [97, 98]. Given that there is no regulated pathway
to excrete iron from the body, the iron balance is primarily
preserved by the regulation of iron absorption from the
duodenum and iron recycling from myeloid cells and other
tissue stores (primarily within hepatocytes) [99].
Iron exported from enterocytes or cells from theMYPS is
bound with high affinity to transferrin (Tf), a glycoprotein
produced in the liver and able to bind one or two iron
molecules. Tf has a dual function (i) limiting iron-catalyzed
free radical production and (ii) facilitating iron transport to
all cells within the host that requires iron [100]. Alternatively,
circulating copper-carrying ceruloplasmin can also partic-
ipate in iron transport [101]. Under steady state situations
iron-bound Tf (holotransferrin) is taken up via endocytosis
by cells that express the Tf receptor (Tf-R) in order to
fulfill normal metabolism, DNA synthesis, and RBC produc-
tion. Important to mention is that the mammalian Tf-R is
a homodimeric transmembrane glycoprotein consisting of
two identical monomers joined together by two disulphide
bonds and composed of a short cytoplasmic NH2-terminal
cytoplasmic region (residues 1–67), a single transmembrane
pass (residues 68–88), and a large extracellular portion
(residues 89–760) containing the Tf binding region. It can
bind two molecules of Tf with an affinity of 10 nM [102–104].
There are two isoforms, Tf-R1 (expressed by all nucleated
cells) and TfR-2 (restricted to hepatocytes and immature
erythroid cells), present within the mammalian host that
are different from the trypanosomal Tf-R. In addition, Tf-
R1 levels are regulated by cellular iron levels while Tf-R2
levels are regulated by Tf saturation and reported to bind
diferric Tf although with 25 times lower affinity than Tf-
R1. Also at the level of the kidney, some Tf which is an
essential growth factor in the development of kidney and
differentiation of tubules normally enters glomerular filtrate,
but it ismainly retrieved by specific receptor-mediated uptake
in the kidney tubular system. The Tf-R is expressed on the
apical membrane of proximal tubule and collecting duct cells.
Also, in the proximal tubule, the cubilin receptor, which is
highly expressed on the apical membrane of kidney proximal
tubules, is thought to mediate uptake of Tf [105]. Of note,
similar to trypanosomes, mammals are able to bind Tf via
GADPH, albeit with lower affinity [106, 107].
Internalization of the iron-Tf-R complexes is initiated fol-
lowing receptor phosphorylation by protein kinase-C (PKC).
Following uptake of holo-Tf, the lower pH of the endo-
some/phagolysosome triggers the release of iron and recy-
cling of the apo-Tf/Tf-R complex to the cell surface, whereby
the apo-Tf is released due to the neutral pH. Subsequently,
ferric iron is reduced and transported into the cytoplasm
by Nramp1 (a divalent metal transporter homologous to
DMT1 expressed at the phagolysosomalmembrane) where its
faith depends on the cellular needs: (i) stored in ferritin (a
large globular protein-complex able to bind up to 4500 iron
molecules) or (ii) exported/released back into circulation via
the basolateral transmembrane iron transporter ferroportin
(FPN1/SLC40A1) followed by oxidization of the ferrous form
back to the ferric form via ceruloplasmin. As mentioned
before, to meet the cellular needs of the body and to prevent
cellular damage by iron, the amount of iron in the body must
be tightly regulated. Hereby, the liver is a central regulator
of systemic iron homeostasis through secretion of the 25-
amino-acid peptide hormone hepcidin mainly by hepato-
cytes [99, 108, 109]. Furthermore, the hepcidin production
is also regulated via different triggers, whereby iron levels,
proinflammatory cytokines (such as IL-1, IL-6, and IL-22),
TLR activation, or endoplasmatic reticulum stress stimulate
its production, whereas erythropoiesis, anemia, hypoxia,
hormones (estrogen), and growth factors (epidermal growth
factor, hepatocyte growth factor) decrease its production
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Figure 2: Ironmodulation and pathogenicity development duringT. brucei infection. Trypanosomes are equippedwith differentmolecules to
acquire iron from themammalian host, namely, via their ESAG6/7 Tf-R (involved in Tf uptake), GADPHLf-R (involved in Lf uptake), and the
HbHpR (involved in heme/hemoglobin uptake). Parasites release molecules like the GPI-anchor or CpG-DNA to modulate/activate the host
MYPS for their own benefit (1). Most of these molecules released by death or phagocytosed parasites trigger the release of proinflammatory
molecules by M1-type myeloid cells, including Gal-3 and MIF (2). Both molecules stimulate iron-retention by inducing expression of HO-
1, DMT-1, and FHC and by decreasing expression of FPN-1 within M1-type MYPS cells (3). Gal-3 by stimulating erythrophagocytosis (4)
and MIF by suppressing erythropoiesis (5) contribute to anemia development. Due to their antiapoptotic effect, Gal-3 and MIF favor the
persistence of the pathogenic M1-type MYPS. Moreover, MIF contributes to the recruitment of other pathogenic myeloid cells such as
monocytes and neutrophils and further fuels the development of liver injury (6). GPI: glycosylphosphatidylinositol; Gal-3: galectin-3; MIF:
macrophage migration inhibitory factor; Tf: transferrin; Tf-R: transferrin-receptor; Lf: lactoferrin; Lf-R: lactoferrin-receptor; HO-1: heme
oxygenase 1; DMT-1: Divalent metal ion transporter 1; FPN-1: ferroportin-1; ESAG6/7 Tf-R: expression-site-associated genes (ESAG) 6 and 7;
GAPDH: glyceraldehyde-3-phosphate dehydrogenase; HpHbR: haptoglobin-hemoglobin receptor; MYPS: myeloid phagocyte system. Figure
adapted from [20].
[94, 110–114]. Of note, neutrophils and myeloid cells can
also synthesize minute amounts of hepcidin in response to
infectious agents, thereby allowing the modulation of iron
availability in an autocrine fashion at the infectious focus
[115, 116]. Following binding of hepcidin to the principal iron
exporter FPN-1 at the cell surface, this latter is internalized
and subsequently lysosomally degraded [117]. As a result,
the export of iron is blocked, and iron is sequestrated at
the level of the enterocytes, myeloid cells, and hepatocytes
[109]. As mentioned before, limiting the iron availability
for extracellular pathogens is considered to be a defense
mechanism of the body, yet, reducing the levels of circulating
iron can also culminate in anemia development [1, 118].
4. Iron Homeostasis/Acquisition in
the Mammalian Host during African
Trypanosome Infection
In livestock populations, anemia is considered the major
cause of death during African trypanosomosis, and
the capacity to limit anemia is critical in determining try-
panotolerance [119]. The occurrence in infected cattle of
hyper activated M1-type myeloid cells and massive eryth-
rophagocytosis by tissue-associated MYPS cells as well as a
modulated iron homeostasis suggests that these factors can
be major causes of anemia [120, 121].
To unravel the mechanisms underlying African trypano-
somosis-elicited anemia development, murine models (fo-
cusing on T. brucei trypanosomosis) exhibiting different
degrees of anemia development were scrutinized. Although
these mouse models show limitations, they have contrib-
uted significantly to our current understanding of trypanoso-
mosis-associated anemia development [13, 20, 122]. In T.
brucei-infected mice, anemia level does not correlate with
parasitemia levels, antibody and T-cell responses, or survival
time [119, 123], similar to bovine trypanosomosis [119, 124],
suggesting that anemia is a consequence of the host immune
response rather than of a direct influence of parasite products
on RBC viability.
Anemia development during the course of experimen-
tal T. brucei infection can be divided into two phases
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(reviewed in [20, 125]): (i) an acute phase whereby M1-
activated myeloid cells (i.e., classically activated myeloid
cells) eliminate/phagocytose RBCs mainly in the liver and
the spleen, resulting in activation of pathways that govern
iron homeostasis and (ii) a short-lived and partial recovery
of RBC levels, which is most likely due to extramedullar
erythropoiesis (at the level of the spleen and liver) in response
to the acute anemia in an attempt to restore RBC numbers,
followed by a chronic and progressive phase. During this
phase, persistence of M1-type cells of the MYPS reduces
iron bioavailability by retaining iron in storage sites within
the MYPS, thereby diverting iron from erythropoiesis. In
this chronic phase, the enhanced uptake of both RBCs and
iron-containing compounds is maintained, which aggravates
anemia development [125]. The upregulation in whole tissue
and cells of the MYPS of molecules involved in import (HO-
1/DMT-1) and storage (FHC) of iron and downregulation of
the cellular iron export regulator (FPN-1) provides additional
evidence for an augmented liver and spleen iron-metabolism
and accelerated senescence of RBCs during African try-
panosome infection in trypanosusceptible animals (Figure 2)
[125, 126]. Moreover, erythropoiesis was shown to be sup-
pressed during the course of trypanosome infections [126–
128]. It should also be remarked that iron accumulation inM1-
type cells of the MYPS can also contribute to oxidative stress
and NF-𝜅B activation [129–131], thereby contributing to liver
pathogenicity occurring duringAfrican trypanosomosis [132,
133]. Thus, although limiting iron availability for pathogens
during the acute phase of infection as an “iron withholding
strategy” can prevent parasite development and benefit the
host [1, 2], persistence of this response in the chronic
phase of infection can disadvantage the host. Indeed, iron
sequestration byMYPS cells can fuel theirM1-type activation
status and limit iron availability for erythropoiesis [134],
thereby contributing to persistence of anemia.
5. Immune Modulation of Iron
Homeostasis in the Mammalian Host during
African Trypanosome Infection
The anemia induced during African trypanosomosis in
mice, which is characterized by an imbalance between ery-
throphagocytosis and erythropoiesis and by an altered iron
recycling and sequestration by MYPS cells, relates to the so-
called anemia of chronic disease (ACD) [20, 90]. Studies
over the past years aiming at unraveling the underlying
mechanisms involved in anemia development during T.
brucei infection have shown the following:
(i) IFN-𝛾, TNF, TNF-R2, and MyD88-deficient mice
exhibit lower anemia levels as compared to control
wild-type C57Black/6 mice [135–138]. Accumulated
data suggest that the MyD88-dependent activation of
the innate immune response results in the induction
of IFN-𝛾 by T cells. Subsequently, TNF production
is triggered, whereby TNF-R2 signaling plays a key
role in the induction of pathogenicity. In fact, the
increased ratio of TNF over its soluble TNF-R2,
not TNF levels per se, relates to the occurrence of
infection-associated anemia [136].
(ii) The activation state of cells of the MYPS plays
a detrimental role in pathogenicity development,
whereby M1-type MYPS cells (classically activated
myeloid cells) in trypanosusceptible animals (exhibit-
ing severe anemia/ACD) triggered via IFN-𝛾 and/or
molecules acting via TLR signaling promote the pro-
duction of proinflammatory cytokines (such as TNF
and IL-6) and the sequestration of iron. In contrast,
M2-type MYPS cells (alternatively activated myeloid
cells) in trypanotolerant animals (exhibiting reduced
anemia/ACD) induced via IL-10 or IL4/IL13 promote
induction of anti-inflammatory cytokines like IL-
10 (crucial for dampening the pathogenic effects of
proinflammatory cytokines) and export of iron [139–
141]. Moreover, trypanotolerant animals in contrast
to trypanosusceptible animals exhibit a restored iron
homeostasis and increased iron availability for ery-
thropoiesis [127].
(iii) A comparison between trypanosusceptible and
trypanotolerant animals allowed identification of
two host-derived pleotropic molecules, Galectin-3
and macrophage migration inhibitory factor (MIF),
which are strongly upregulated in T. brucei infected
mice. Galectin-3 (Gal-3), a lectin contributing to
the onset and persistence of type-1 inflammatory
responses and phagocytosis, was shown to be
involved in trypanosomosis-associated anemia
development [142]. Hereby, T. brucei infected
galectin-3 deficient mice exhibit greatly reduced
anemia levels coinciding with a restored iron
homeostasis and an increased IL-10 level that
in turn leads to reduced liver destruction. With
respect to MIF, we recently showed that MIF
deficient animals feature limited anemia, which
coincides with a reduced proinflammatory immune
response, an increased iron bioavailability, improved
erythropoiesis, reducedRBC clearance, and increased
IL-10 levels associated with decreased liver injury
during the chronic phase of infection [143]. In
addition, neutrophil-derived MIF contributed more
than monocyte-derived MIF to pathogenicity during
T. brucei infection. Collectively, these results suggest
that the M1-type MYPS cell associated molecules
galectin-3 andMIF both promote themost prominent
pathological features of experimental trypanosome
infections (anemia and liver injury) (Figure 2).
Besides identifying host-derived molecules involved in
triggering/maintaining M1 cells and consequently being
detrimental in anemia development/iron sequestration, the
identification of parasites-derived molecules triggering M1-
typeMYPS cell development could have potential therapeutic
applications. In this context, the trypanosomal GPI-anchor
was shown to be the most potent parasite-derived molecule
able to trigger M1-type myeloid cells [144, 145]. Moreover,
a GPI-based intervention strategy was found to alleviate
trypanosomosis-associated anemia development by lowering
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the proinflammatory cytokine production (including TNF,
MIF, and Gal-3) and increasing IL-10 production [146]. In
addition, this treatment strategy restores iron homeostasis
at the level of the liver (increased iron export and reduced
storage) and increases erythropoiesis in the bonemarrow and
the spleen [127]. This suggests that reprogramming MYPS
cells towards an anti-inflammatory state can be a promising
tool to alleviate ACD, normalize iron homeostasis, and
restore erythropoiesis. Although most trypanosomes cannot
be considered natural pathogens for rodents, murine models
represent excellent tools to study trypanosome biology and
their interaction with the mammalian immune response.
Furthermore, research so far on HAT patients suggests that
TNF is also involved in immunopathogenesis of late stage
African trypanosomosis and that IL10 plays an important
regulatory role in the disease [122]. In addition, chemokines
documented to contribute to pathogenesis such as CCL2
and CXCL10 within the murine model were also found in
cerebral spin fluid (CSF) ofHATpatients [147–149]. Yet, more
additional work should be devoted to determine whether
results from the murine model reflect observations in HAT
patients.
6. Blocking Iron Uptake/Homeostasis at
the Level of the African Trypanosome
Iron deprivation may represent a new strategy for treatment
of African trypanosomosis. However, so far there is only a
limited amount of drugs documented to block trypanosomal
iron uptake or metabolism. The iron chelator/siderophore
deferoxamine/desferoxamine (DFO) produced by Strepto-
myces pilosus has been developed into the drug Desferal
which is used for the treatment of acute iron poisoning
and chronic iron-overload. DFO also stops T. brucei parasite
growth in vitro [150, 151]. This compound does not inhibit
iron-containing enzymes directly but acts by chelating cellu-
lar iron, thus compromising the activity of Fe3+-containing
enzymes such as ribonucleotide reductase, which is involved
in DNA synthesis, and thereby preventing its incorporation
into newly synthesized apoproteins. In their quest to identify
novel iron-chelating molecules, the group of Merschjohann
and Steverding [150] has shown that although most iron
chelators tested so far also display some cytotoxicity to mam-
malian cells, only lipophilic iron-chelating agents represent
potential as novel antitrypanosomal drugs. However, so far
there are no published studies of the effect of direct iron
chelation on T. brucei infection in animal models.
7. General Conclusions/Perspectives
Given that all organisms on earth depend on iron to fulfill
vital cellular functions, there is a continuous quest of both
pathogen and host to acquire this primordial metal. As far
as parasites like African trypanosomes are concerned, their
complex lifecycle alternating between the tsetse fly vector
and the mammalian host adds an additional problem in the
struggle for the supply of this metal.
At the level of the mammalian host, the concept that
polarization of cells of the MYPS into distinct M1-type or
M2-type activation states contributes to trypanosusceptibility
or tolerance, respectively, suggests that reprogramming of
MYPS cells may provide new therapeutical modalities in the
treatment of infection-associated pathogenicity development
[15]. However, additional research is required to dissect the
exact contribution of the different liver and spleen associated
MYPS cell subsets (Ly6c+ and Ly6c− monocytes, resident
and Ly6c+ monocyte-derived macrophages, granulocytes,
and dendritic cells) in erythrophagocytosis or modulation of
iron homeostasis and to Gal-3 or MIF production. Recently,
a mammalian MIF homologue D-dopachrome tautomerase
(D-DT or MIF2) has been identified [152], but its role during
African trypanosomosis-associated pathogenicity develop-
ment (anemia) remains to be investigated.
At the level of the parasites, strategies able to block
parasites’ endocytosis of iron-containing molecules can form
alternative approaches to control parasite development and
survival [153–156]. Hereby, blockage of uptake of iron or of
iron-containing compounds via antagonists or antibodies is
promising. For instance, the specificity of the trypanosomal
(ESAG6/7) Tf-R makes it a potential target to deliver toxic
molecules inside the parasite [47]. In this context, a therapy
based on nanobodies (Nbs) which are camelid derived single-
domain antibody fragments [157] was found efficient in
targeting drugs to African trypanosomes [158]. Also, Nbs
able to block endocytic capacity of the parasite were found
to block transferrin uptake thereby killing the trypanosome
[156]. Moreover, a functional T. brucei Tf-R was expressed
in insect cells which could be helpful in crystallographic
studies to determine the structure and characterize the
interface between Tf and its receptor, which could lead to
a new approach to combat infection [159]. Alternatively,
the GPI-biosynthesis pathway which is crucial in parasites’
viability may represent another therapeutic approach for
trypanosomosis [160]. In addition, future efforts should
also aim at improving the selectivity of iron chelators, for
instance, by utilizing the wealth of information currently
being generated in the development of cell-permeable iron
chelators as cancer chemotherapeutic agents [161]. Moreover,
iron chelators could be of interest for combination ther-
apy with existing antitrypanosome drugs like, for instance,
DFMO (eflornithine) [31]. Indeed, eflornithine (Ornidyl),
by blocking polyamine (spermidine) biosynthesis and con-
sequently by preventing the production of the antioxidant
trypanothione synthesis by the African trypanosome [162],
may cause oxidative stress by increasing the level of iron
available for the Fenton reaction [163, 164]. However, it
should be taken into consideration that the administration
of iron chelators is not exempt from risks for the host
due to their iron withholding activity which may lead to
anemia. African trypanosomes are heme auxotrophs and are
dependent on specialized transporters to import heme [165,
166]. Drug targeting of this transport pathway may be more
valuable to target the insect stage of African trypanosomes
where the heme import is more important than for the
mammalian bloodstream stage of the parasite.
Despite the progresses achieved in the last years, more
studies on the role of iron in the parasite development and on
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modulation of ironmetabolism in infected hosts are required
before translation of this knowledge into effective treatments.
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